>학술정보> 학술논문
 
  학술논문
 
   제목   Using microbubble sonographic contrast agent to enhance the effect of high intensity focused ultrasound for the treatment of uterine fibroids.
   작성자   관리자     작성일   2015-12-28
   이메일       조회수   247
   첨부파일 없음 없음 없음
 
Ultrason Sonochem. 2015 Jun 9. pii: S1350-4177(15)00156-X. 


Using microbubble sonographic contrast agent to enhance the effect of high intensity focused ultrasound for 
the treatment of uterine fibroids.

Isern J, Pessarrodona A, Rodriguez J, Vallejo E, Gimenez N, Cassado J, De Marco JA, Pedrerol A.

HIFU Unit, University Hospital Mutua de Terrassa, Spain; Department of Obstetrics and Gynecology, University 
Hospital Mutua de Terrassa, Spain.

HIFU Unit, University Hospital Mutua de Terrassa, Spain; Department of Obstetrics and Gynecology, University 
Hospital Mutua de Terrassa, Spain. Electronic address: apessarrodona@mutuaterrassa.es.

Department of Radiology, University Hospital Mutua de Terrassa, Spain.

Department of Obstetrics and Gynecology, University Hospital Mutua de Terrassa, Spain.

OBJECTIVE: To evaluate the effects of the ultrasound contrast agent SonoVue in enhancing the ablative 
effects of Ultrasound-Guided high-intensity focused ultrasound (HIFU) on different sub-types of uterine 
fibroids.

MATERIALS AND METHODS: In this study, 390 fibroids from 319 patients were retrospectively evaluated, among 
which 155 were treated with SonoVue and 235 were without SonoVue during HIFU ablation. The efficacy of HIFU 
was evaluated using magnetic resonance scanning (MRI) in all patients.
 
RESULTS: The total ablation time to achieve the same non-perfused volume was significantly shortened with 
SonoVue. The average energy used and the acoustic energy for treating 1mm3 (EEF) was less when SonoVue is 
used as enhancing agent. The non-perfused volume (NPV) was measured by post-HIFU MRI and the mean fractional 
ablation was calculated. Mean NPV was 74% (range: 15%-100%) in the HIFU-only group and 75% (range: 17%-100%) 
in the HIFU+ SonoVue group. However, for T2 MRI low intensity signal fibroids, NPV in the SonoVue group 
reached 83% (range: 20%-100%) that was significantly higher than in the HIFU-only group, which was 76% 
(range: 15%-100%). No differences in adverse events were observed between the two groups.

CONCLUSIONS: Our observations demonstrate that the use of therapeutic SonoVue during the HIFU procedure can 
significantly decrease the ablation time and the energy requirement for the treatment of the same fibroid 
volume in all types of fibroids.

PMID: 26113390

출처: http://www.ncbi.nlm.nih.gov/pubmed/?term=26113390



     
 
         

회사소개

인사말

연혁

오시는길

하이푸

하이푸

 


제품소개

PRO2008
SONACARE
ECHOPULSE

학술정보

학술논문

수술사례

 

고객지원

ECHO & NEWS

동영상자료

FAQ

    Family Site : http://www.echotherapy.co.kr